<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02591082</url>
  </required_header>
  <id_info>
    <org_study_id>RR2</org_study_id>
    <nct_id>NCT02591082</nct_id>
  </id_info>
  <brief_title>Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter</brief_title>
  <official_title>A Multi-Center, Post-Marketing, Prospective, Observational Study Following Treatment With Intra-Arterial Delivery of Chemotherapeutic Agents Using the RenovoCath™ RC120 Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenovoRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenovoRx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study to assess patient survival and clinical outcomes after the
      RenovoCath™ RC120 catheter is used to deliver chemotherapeutic agents to pancreatic tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, registry study to assess patient survival and clinical outcomes of
      the RenovoCath™ RC120 catheter when used to deliver chemotherapeutic agents to pancreatic
      tumors. Blood samples will be drawn in a subset of patients to assess the systemic
      concentration of the chemotherapeutic agent.

      The RenovoCath™ RC120 Catheter is an endovascular multi-lumen, two-handled catheter designed
      to isolate variable segments of arteries supplying the target organ using two slideable,
      compliant balloons. Upon inflation of the proximal occlusion balloon and the distal occlusion
      balloon, the catheter may isolate the selected site to specifically deliver radiopaque and
      therapeutic agents including, but not limited to chemotherapeutic drugs.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>2 Years</time_frame>
    <description>Duration of survival in patients diagnosed with pancreatic cancer who undergo intra-arterial delivery of chemotherapeutic agents to the pancreas</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>6 months</time_frame>
    <description>Time to tumor response in the primary site of application as assessed by imaging.</description>
  </secondary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RenovoCath™ R120 Catheter</intervention_name>
    <description>The RenovoCath™ RC120 Catheter will be used to isolate segments of arteries supplying blood to the pancreas. The two balloons on the catheter will be positioned and inflated to temporarily stop blood flow while medication is infused through the catheter between the balloons.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with unresectable or borderline resectable pancreatic cancer.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age

          -  Diagnosed with unresectable or borderline resectable pancreatic adenocarcinoma
             confirmed by histology or cytology

          -  Without current myelotoxicity and with sufficient health status to undergo a
             catheterization procedure

          -  Willing to provide informed consent and comply with the required follow-up.

        Exclusion Criteria:

          -  Have received prior chemotherapy and/or radiation therapy within 14 days prior to the
             first intra-arterial treatment.

          -  Currently participating in another active drug or device study or registry protocol
             that would interfere with this study.

          -  Vulnerable populations: prisoners, pregnant or breastfeeding females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramtin Agah, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fawcett Memorial Hospital</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Hospital</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 27, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2015</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

